癌胚抗原检测的现状

Current status of carcinoembryonic antigen assay.

作者信息

Chu T M

出版信息

Semin Nucl Med. 1975 Jul;5(3):255-62. doi: 10.1016/s0001-2998(75)80013-4.

Abstract

The carcinoembryonic antigen (CEA) is a glycoprotein that can be measured by radioimmunoassay and other immunologic techniques. The CEA reagent is currently commercially available in kit form and has been found to be satisfactory for laboratory use. The highest percentage of elevated plasma CEA and the highest CEA titer have been found in patients with entodermally derived tumors. CEA has also been detected in patients with other tumors and in patients with nonneoplastic disease, as well as in heavy cigarette smokers. The present CEA assay cannot be used to screen for cancer in the general population. The greatest clinical usefulness of current CEA assay is in assessing prognosis, in the detection of residual tumors and recurrent disease, and in monitoring chemotherapy and radiotherapy. The use of anti-CEA antiserum as a tumor-localizing agent may be of potential value in the future.

摘要

癌胚抗原（CEA）是一种糖蛋白，可通过放射免疫测定法和其他免疫技术进行检测。CEA试剂目前有试剂盒形式的商业产品，已被证明适用于实验室使用。在内胚层来源肿瘤患者中发现血浆CEA升高的比例最高，CEA滴度也最高。在其他肿瘤患者、非肿瘤性疾病患者以及重度吸烟者中也检测到了CEA。目前的CEA检测不能用于普通人群的癌症筛查。当前CEA检测最大的临床用途在于评估预后、检测残留肿瘤和复发疾病以及监测化疗和放疗。抗CEA抗血清作为肿瘤定位剂的应用在未来可能具有潜在价值。